Soo Park
University of California, San Diego · UC San Diego Health - Moores Cancer Center · Seoul
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Registry trials as an overall official
37
all conditions, ClinicalTrials.gov
NIH grants tied to them
0
13 more share only the name and are not shown
Trial papers
2676
PubMed author-name match
Trials
Studies that name Soo Park as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 01:09 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07803562 · Low Dose Dexamethasone for the Prevention of Cytokine Release Syndrome Associated With TebentafuspUniversity of California, San Diego · withdrawn · Uveal Melanoma, Metastatic · principal investigator
- Ph2NCT06624475 · Neoadjuvant Nivolumab + Relatlimab (Opdualag) Versus Nivolumab for Resectable High-Risk Basal Cell CarcinomaUniversity of California, San Diego · recruiting · Basal Cell Carcinoma · principal investigator
- N/ANCT06205823 · Compare Clinical Outcomes Between Advanced Immunotherapy and Classical Immunochemotherapy in RRMMSeoul St. Mary's Hospital · unknown · Myeloma Multiple · study director
- N/ANCT05830422 · Prediction of Delayed Cognitive Impairment in Cardiac Arrest Survivors With Good Neurological OutcomesChungnam National University Hospital · enrolling by invitation · Cardiac Arrest, Out-Of-Hospital, Cognitive Impairment · study chair
- N/ANCT05588544 · YSGG Application in Periodontal TreatmentKorea University Anam Hospital · completed · Periodontal Diseases · principal investigator
- Ph1NCT04840745 · The Safety and Pharmacokinetic/Pharmacodynamic Study of CKD-841 in Postmenopausal Female, Phase 1Chong Kun Dang Pharmaceutical · unknown · Early Puberty · principal investigator
- Ph1NCT04810676 · A Clinical Trial to Evaluate the Pharmacokinetic Profiles and Safety of CKD-383.Chong Kun Dang Pharmaceutical · completed · Type2 Diabetes Mellitus · principal investigator
- Ph1NCT04768673 · A Study to Investigate the PK and Safety of CKD-393Chong Kun Dang Pharmaceutical · completed · Type II Diabetes · principal investigator
- Ph4NCT04700436 · Efficacy and Safety of EzetimiBe/Rosuvastatin in Diabetic Dislipidemia With HypertriglyceridaemiaSeoul National University Hospital · completed · Endocrine System Diseases, Nutritional and Metabolic Diseases, Diabetes Mellitus, Type 2 · principal investigator
- Ph1NCT04246190 · A Clinical Study to Evaluate the Pharmacokinetics and Safety of CKD-396Chong Kun Dang Pharmaceutical · unknown · Type2 Diabetes Mellitus · principal investigator
- Ph1NCT04221360 · A Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD-375Chong Kun Dang Pharmaceutical · unknown · Type2 Diabetes Mellitus · principal investigator
- Ph1NCT04171687 · Effect of Tegoprazan or RAPA113 on Pharmacodynamics/Pharmacokinetics of Clopidogrel in Healthy Male VolunteersHK inno.N Corporation · completed · Healthy · principal investigator
- Ph1NCT03849339 · Pharmacokinetics and Safety/Tolerability After Oral Administration of CKD-387 and D635 Under Fed ConditionChong Kun Dang Pharmaceutical · unknown · Type 2 Diabetes Mellitus · principal investigator
- Ph1NCT03849261 · Pharmacokinetics and Safety/Tolerability After Oral Administration of CKD-387 and D635 in Healthy AdultsChong Kun Dang Pharmaceutical · unknown · Type2 Diabetes Mellitus · principal investigator
- Ph1NCT03766724 · Pharmacokinetic and Pharmacodynamic Drug-Drug Interaction of Evogliptin and Empagliflozin or Dapagliflozin in Healthy Male AdultsDong-A ST Co., Ltd. · completed · Type2 Diabetes · principal investigator
- Ph1NCT03738449 · The Clinical Trial to Investigate the Pharmacokinetics and Safety/Tolerability of CKD-387 Under Fed ConditionChong Kun Dang Pharmaceutical · completed · Type 2 Diabetes Mellitus · principal investigator
- Ph1NCT03646799 · Pharmacokinetics and Safety/Tolerability After Oral Administration of CKD-387 and D484 in Healthy AdultsChong Kun Dang Pharmaceutical · unknown · Type II Diabetes · principal investigator
- Ph1NCT03233932 · CKD-841 Pharmacokinetic/Pharmacodynamic StudyChong Kun Dang Pharmaceutical · completed · Postmenopausal Disorder · principal investigator
- Ph3NCT03196791 · Compare the Oncological Benefit of Deep Neuromuscular Block in Gastric Cancer Obesity PatientKorea University Anam Hospital · completed · Gastric Cancer, Obesity · principal investigator
- Ph1NCT02916901 · Study to Investigate the Influence of CKD-519 on 24-h Ambulatory Blood Pressure in Healthy Adult VolunteersChong Kun Dang Pharmaceutical · completed · Healthy Volunteers · principal investigator
- Ph1NCT02700360 · Evaluation of the Food Effect on the Safety, Tolerability, PK of EC-18 After Oral Administration in Healthy VolunteersEnzychem Lifesciences Corporation · completed · Chemotherapy-Induced Neutropenia · principal investigator
- Ph3NCT02587845 · Use of Transexamic Acid in Hip ReplacementSamsung Medical Center · unknown · Bleeding, Transfusion Related Complication · study director
- Ph1NCT02532712 · Study to Evaluate the Safety, Tolerability and PK of EC-18 After Oral Administration in Healthy VolunteersEnzychem Lifesciences Corporation · completed · Chemotherapy-Induced Neutropenia · principal investigator
- Ph1NCT02330003 · Phase 1 Study to Assess the Safety of Inactivated Split Influenza Vaccine and Control Vaccine in Korean VolunteerIl-Yang Pharm. Co., Ltd. · completed · Healthy · principal investigator
- Ph1NCT02288338 · CKD-391 DDI : Atorvastatin and Ezetimibe in Healthy VolunteersChong Kun Dang Pharmaceutical · completed · Healthy · principal investigator
- Ph1NCT02176668 · The Exploration for Pharmacodynamics and Pharmacokinetics of YH4808 New Formulation in Healthy SubjectsYuhan Corporation · completed · Healthy · principal investigator
- Ph1NCT02146625 · Safety, Tolerability, PK, PD, ADA of Escalating Single Dose of CJ-40002 in Healthy Male SubjectsHK inno.N Corporation · completed · Healthy · principal investigator
- Ph1NCT02005744 · A Pharmacokinetic Study of CKD-501 in Patients With Impaired Hepatic FunctionChong Kun Dang Pharmaceutical · completed · Liver Dysfunction · principal investigator
- Ph1NCT01929213 · Clinical Trial to Investigate the Pharmacokinetic Drug Interaction Between Udenafil and Bosentan After Oral AdministrationDong-A Pharmaceutical Co., Ltd. · unknown · Healthy Volunteers · principal investigator
- N/ANCT01922492 · Effect of Islet Autotransplantation Compared to Oral Antidiabetic Drug.Seoul National University Hospital · unknown · Partial Pancreatectomy Due to Benign Pancreatic Neoplasm · principal investigator
- Ph1NCT01921647 · The PK and PD Interaction Between YH4808, Amoxicillin and Clarithromycin in Healthy SubjectsYuhan Corporation · completed · Healthy · principal investigator
- Ph4NCT01888536 · A Study to Evaluate Efficacy of 『Opast Tablet』for Neurologic Claudication in Patients With Lumbar Spinal StenosisYungjin Pharm. Co., Ltd. · completed · Neurologic Claudication in Patients With Lumbar Spinal Stenosis · principal investigator
- Ph1NCT01842256 · Study to Investigate the Effect of Telmisartan/S-amlodipine on the Pharmacokinetic Properties of Atorvastatin.Chong Kun Dang Pharmaceutical · completed · Essential Hypertension, Hyperlipidemia · principal investigator
- Ph1NCT01842230 · Study to Investigate the Effect of Atorvastatin on the Pharmacokinetic Properties of Telmisartan/S-amlodipineChong Kun Dang Pharmaceutical · completed · Essential Hypertension, Hyperlipidemia · principal investigator
- Ph1NCT01820715 · A Study to Evaluate the Safety of DA-3030 and to Explore the Efficacy for Diabetic Neuropathic PainDong-A Pharmaceutical Co., Ltd. · completed · Diabetic Neuropathy · principal investigator
- Ph4NCT01768468 · To Compare the Efficacy and Safety of LAYLA in Osteoarthritis PatientsPMG Pharm Co., Ltd · completed · Osteoarthritis of the Knee · principal investigator
- Ph3NCT00699543 · The Efficacies of The New Paclitaxel-Eluting CoroflexTM Please Stent in Percutaneous Coronary InterventionSeoul National University Hospital · unknown · Coronary Artery Disease · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 01:09 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 13 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 01:09 UTC. The ranking covers the 200 most relevant of 2676 PubMed records, and a shared surname and initials can bring in a namesake. All 2676 on PubMed
- 1,002 citationsRCR 130.6
- 309 citationsRCR 23.8
- Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma.N Engl J Med · 2024301 citationsRCR 35.7
- Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma.N Engl J Med · 2023299 citationsRCR 26.3
- Efficacy and Safety of Bepirovirsen in Chronic Hepatitis B Infection.N Engl J Med · 2022270 citationsRCR 20.1
- 260 citationsRCR 41.8
- 259 citationsRCR 16.8
- Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From the JAVELIN Bladder 100 Trial After ≥2 Years of Follow-Up.J Clin Oncol · 2023203 citationsRCR 16.2
- Phase III, Randomized Study of Atezolizumab Plus Bevacizumab and Chemotherapy in Patients With EGFR- or ALK-Mutated Non-Small-Cell Lung Cancer (ATTLAS, KCSG-LU19-04).J Clin Oncol · 2024180 citationsRCR 18.8
- Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma.N Engl J Med · 2024176 citationsRCR 20.7